TELA Bio, Inc. Debt Securities, Available-for-sale, Unrealized Loss
TELA Bio, Inc. (TELA) reported Debt Securities, Available-for-sale, Unrealized Loss of $4.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2022-03-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2022-03-23
- TELA Bio, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2019 was $4.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|
| 2019-12-31 | $4.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| NEPHROS INC (NEPH) | United States | $0.046B | 23.02 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| InspireMD, Inc. (NSPR) | $0.033B |